Drug R&D

Largest In Vivo Spontaneous Cancer Dataset and Clinical Trial Platform in the World with
1.8 Billion Datapoints

Our Science

TEDxBoston AI
Can dogs and AI fight cancer?

Veterinary oncology can inform human oncology, and vice versa — providing a better model for looking at drug performance, interrelationships, and more. Especially when you add in data (there’s no “doggy HIPAA!”) and networks to get a “living laboratory at scale”.

Listen to Amy Abernethy, advisor to One Health, on why she’s so excited about the impact of comparative oncology on our investor’s podcast The a16z Podcast.

Fireside Chat with Dr. Len Lichtenfeld, former Deputy Chief Medical Officer, American Cancer Society on 8-year Journey and Impact of AI Data

Exclusive fireside chat with a distinguished trio of cancer experts: Dr. Len Lichtenfeld former Deputy Chief Medical Officer for the American Cancer Society (and FidoCure Scientific Advisory Board Member) with Christina Lopes, CEO, FidoCure and Dr. Gerry Post, Chief Medical Officer, FidoCure. 

Hear first-hand about their 8-year journey together in the fight against cancer on both ends of the leash.

Oncology drug development is broken.

The canine model offers a unique and valuable perspective in the realm of medical research due to its significant advantages over the traditional mouse model.  While mice models have been crucial in various studies, they come with a high failure rate when translating findings to human applications.  Canine models, on the other hand, bridge the gap between preclinical research and clinical trials, serving as a more biologically relevant intermediary.

Failure In Mice To Human Translation
0 %
To Bring Drugs to Market
$ 0 B
From R&D to Patients
0 Years

Only 3-6% Patients Enroll in Clinical Trials

Reimagining the Patient: Dog

Canine biology closely mirrors human physiology and genetics, making it an excellent model for studying complex diseases, such as cancer. This increased relevance and reliability in mimicking human responses make the canine model a promising avenue for enhancing the success rate of research and ultimately improving human health outcomes.

  • Accelerated disease timeline 
  • No standard of cancer care
  • Natural disease & intact immune system
  • Shared environment with humans

Imbruvica Case Study:
Dog data gave signal to unshelve blockbuster drug

Oncology R&D on Both Sides of the Leash​

Our Solution

  • Canine Oncology Clinical Trials: a spontaneous disease model with genetic similarity to human tumors
  • The largest canine cancer clinico-genomic dataset: banked tumor tissue and ability to rapidly identify biomarker-selected patients for prospective trials
  • Access to longitudinal outcomes data in real time with repeat biopsy potential during treatment
  • Extensive canine cancer network and expertise

The Impact

  • Accelerate R&D through a better approximation of clinical disease in humans
  • De-risk R&D pipeline by providing proof-of-concept animal model to help reduce late-stage failures
  • Generate robust pre-clinical data to discover new predictive biomarkers and evaluate combination therapies for advancing novel treatments for human health

Our Most Valuable Asset: Data